RECURRENT WHO GRADE II GLIOMA
Clinical trials for RECURRENT WHO GRADE II GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WHO GRADE II GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT WHO GRADE II GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for young brain tumor patients: drug duo targets genetic mutations
Disease control OngoingThis early-stage study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in adolescents and young adults with IDH1/2-mutant gliomas, a type of brain tumor. The goal is to find the safest dose and check for side effects. About 78 participants with newly diagnose…
Matched conditions: RECURRENT WHO GRADE II GLIOMA
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 26, 2026 08:57 UTC
-
Engineered immune cells take on recurrent brain tumors in early trial
Disease control OngoingThis early-stage study tests a new treatment for people with malignant glioma that has returned or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), add a special gene to help them recognize and attack the tumor, and infuse them back. The mai…
Matched conditions: RECURRENT WHO GRADE II GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
New hope for brain cancer: engineered immune cells target tumors
Disease control OngoingThis early-phase study tests a new type of immune cell therapy (CAR T cells) designed to target a protein called MMP2 found on glioblastoma brain tumors that have returned or worsened. The main goals are to find the safest dose and understand side effects. About 19 participants w…
Matched conditions: RECURRENT WHO GRADE II GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC